These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 30855309)

  • 1. Oxazaphosphorine cytostatics: from serendipity to rational drug design.
    Voelcker G
    Anticancer Drugs; 2019 Jun; 30(5):435-440. PubMed ID: 30855309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity.
    Voelcker G
    Anticancer Drugs; 2018 Jan; 29(1):75-79. PubMed ID: 29219879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of cyclophosphamide and ifosfamide pharmacology.
    Fleming RA
    Pharmacotherapy; 1997; 17(5 Pt 2):146S-154S. PubMed ID: 9322882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The history of the oxazaphosphorine cytostatics.
    Brock N
    Cancer; 1996 Aug; 78(3):542-7. PubMed ID: 8697402
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of oxazaphosphorine cytostatics on granuloid progenitor cell (CFUc) proliferation in mice.
    Semont H; Hecquet C; Adolphe M; Deysson G
    Exp Hematol; 1982 Oct; 10(9):782-8. PubMed ID: 7173344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.
    Brock N
    Cancer Res; 1989 Jan; 49(1):1-7. PubMed ID: 2491747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safe decontamination of cytostatics from the nitrogen mustards family. Part one: cyclophosphamide and ifosfamide.
    Štenglová Netíková IR; Petruželka L; Šťastný M; Štengl V
    Int J Nanomedicine; 2018; 13():7971-7985. PubMed ID: 30538471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro cytotoxicity testing of new generation oxazaphosphorines against human histiocytic lymphoma cells.
    Opydo-Chanek M; Mazur L; Stojak M
    Indian J Exp Biol; 2013 Aug; 51(8):615-22. PubMed ID: 24228385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene.
    Chen L; Waxman DJ; Chen D; Kufe DW
    Cancer Res; 1996 Mar; 56(6):1331-40. PubMed ID: 8640822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glufosfamide as a new oxazaphosphorine anticancer agent.
    Mazur L; Opydo-Chanek M; Stojak M
    Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide and cyclophosphamide: effects on immunosurveillance.
    Binotto G; Trentin L; Semenzato G
    Oncology; 2003; 65 Suppl 2():17-20. PubMed ID: 14586142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide versus ifosfamide: to use ifosfamide or not to use, that is the three-dimensional question.
    Williams ML; Wainer IW
    Curr Pharm Des; 1999 Aug; 5(8):665-72. PubMed ID: 10469897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of ifosfamide.
    Furlanut M; Franceschi L
    Oncology; 2003; 65 Suppl 2():2-6. PubMed ID: 14586139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity of murine B- and T-lymphocytes to oxazaphosphorine and non-oxazaphosphorine nitrogen mustards.
    Smith PC; Sladek NE
    Biochem Pharmacol; 1985 Oct; 34(19):3459-63. PubMed ID: 3876834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
    Giraud B; Hebert G; Deroussent A; Veal GJ; Vassal G; Paci A
    Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):919-38. PubMed ID: 20446865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiated cyclophosphane: experimental study of the effect on tumor development and efficiency of cytostatic therapy.
    Amosova EN; Zueva EP; Razina TG; Krylova SG; Shilova NV; Epstein OI
    Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():107-10. PubMed ID: 12949669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and its chemoprevention .
    Dobrek Ł; Thor PJ
    Postepy Hig Med Dosw (Online); 2012 Sep; 66():592-602. PubMed ID: 23001201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP.
    Voelcker G
    Anticancer Drugs; 2018 Jun; 29(5):411-415. PubMed ID: 29465464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells.
    Schwartz PS; Waxman DJ
    Mol Pharmacol; 2001 Dec; 60(6):1268-79. PubMed ID: 11723234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics.
    Brock N
    J Cancer Res Clin Oncol; 1986; 111(1):1-12. PubMed ID: 3949846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.